FDA Grants Priority Review to TAS-102 for Gastric/GEJ Cancer
Shared in OncLive, the FDA has granted priority review to a supplemental new drug application for TAS-102 (trifluridine/tipiracil; Lonsurf) for use in... Read More
Taiho Oncology and Servier Announce Positive Results from LONSURF® (trifluridine/tipiracil) Study Presented at ESMO 2018 Congress and Published in The Lancet Oncology
Lonsurf receives FDA priority review for metastatic gastric cancer, with a new study presented at ESMO 2018 Congress and published in The... Read More